GSK plc (GSK) is a biopharmaceutical company focused on discovering, developing, and delivering medicines and vaccines. The company serves therapeutic areas such as respiratory, immunology and inflammation, oncology, HIV, and infectious diseases.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

GSK combines the science of the immune system with advanced technologies, targeted business development, and strategic partnerships to develop new medicines and vaccines. The company undertakes research and development (R&D) initiatives focused on four core therapeutic areas: respiratory; immunology and inflammation; oncology; HIV; and infectious diseases. The company leverages advanced technologies such as human genetics, functional genomics, artificial intelligence, and machine learning to enhance its understanding of human biology and disease mechanisms. This approach is aimed at delivering innovative medicines and vaccines that can transform patient outcomes. GSK also invests in strategic business development to bolster its pipeline and technology capabilities, with a focus on diseases with high patient need. The R&D units of GSK include strategic global hubs in the US, UK, Belgium, Italy, and Spain. These units are responsible for managing the company's R&D activities, including the discovery and development of new medicines and vaccines, and the integration of advanced technologies to accelerate research and development processes. The company has formed major technology alliances, including collaborations with Hengrui, Empirico, and LTZ Therapeutics. In FY2025, the company spent GBP7,525 million on its R&D activities, which as a percentage of revenue, stood at 23.1% and grew 17.6% YoY. As of December 2025, the company has 58 pipeline products, 17 in phase III, and five major FDA approvals. Some of pipeline drugs in phase III include GSK5464714 (camlipixant) to treat refractory chronic cough; GSK3511294 (depemokimab) to treat eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES); GSK4527223 (AL-001) (latozinemab) to treat frontotemporal dementia (FTD) due to heterozygous mutations in the progranulin gene; AH3365 (salbutamol - Ventolin) for Asthma for low carbon version of metered dose inhaler; GSK1550188 (belimumab – Benlysta) to treat interstitial lung disease associated with connective tissue disease; GSK4428859 (EOS884448) (belrestotug) to treat Non-small cell lung cancer combination with novel immunotherapy combinations; GSK3985771 (niraparib – Zejula) to treat 1L maintenance non-small cell lung cancer combination with pembrolizumab; GSK3228836 (bepirovirsen) to treat chronic hepatitis B virus infection; GSK3536829 (Men B vaccine Bexsero) to treat invasive disease caused by N. meninigitidis serogroup B in individuals 2 months of age and older (US); GSK2140944 (gepotidacin Blujepa) to treat uncomplicated urinary tract infection (uUTI); GSK2140944 (gepotidacin) to treat urogenital gonorrhoea (GC); GSK5458448 (ibrexafungerp) to treat invasive candidiasis; GSK3778712 (tebipenem pivoxil) to treat complicated urinary tract infection (cUTI); and GSK4178116 (Varicella New Strain) to treat active immunization for the prevention of varicella in individuals 12 months of age and older.